These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15297772)

  • 41. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
    Reenaers C; Belaiche J; Louis E
    Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
    [No Abstract]   [Full Text] [Related]  

  • 44. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 45. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
    Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe neutropenia following infliximab treatment in a child with ulcerative colitis.
    Sherlock ME; Bandsma R; Ota K; Kirby-Allen M; Griffiths AM
    Inflamm Bowel Dis; 2011 Feb; 17(2):E17-8. PubMed ID: 20824816
    [No Abstract]   [Full Text] [Related]  

  • 47. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 48. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 50. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 52. Infliximab in the treatment of severe ulcerative colitis.
    Jiménez JM
    Rev Esp Enferm Dig; 2004 Feb; 96(2):89-93. PubMed ID: 15255017
    [No Abstract]   [Full Text] [Related]  

  • 53. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab therapy for ulcerative colitis: many unanswered questions.
    Present DH
    Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infliximab for ulcerative colitis.
    Simmons J; Jewell DP
    Dig Liver Dis; 2002 Sep; 34(9):616-8. PubMed ID: 12405245
    [No Abstract]   [Full Text] [Related]  

  • 57. A case of Rothia dentocariosa bacteremia in a patient receiving infliximab for ulcerative colitis.
    Yeung DF; Parsa A; Wong JC; Chatur N; Salh B
    Am J Gastroenterol; 2014 Feb; 109(2):297-8. PubMed ID: 24496430
    [No Abstract]   [Full Text] [Related]  

  • 58. Does it all ADA up? Adalimumab for ulcerative colitis.
    Travis S
    Gut; 2011 Jun; 60(6):741-2. PubMed ID: 21257988
    [No Abstract]   [Full Text] [Related]  

  • 59. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
    Ricart E; Bouma G; Peña AS
    Drugs Today (Barc); 2002 Nov; 38(11):725-44. PubMed ID: 12582457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infliximab-associated Blastomycosis dermatitidis in treatment of ulcerative colitis.
    McCann DA; Smith HL
    Colorectal Dis; 2013 Feb; 15(2):e102-3. PubMed ID: 23046403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.